Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Jason, McDougal Js, R. Holman, S. Stein, D. Lawrence, J. Nicholson, G. Dixon, M. Doxey, B. Evatt (1985)
Human T-Lymphotropic Retrovirus Type III / Lymphadenopathy-Associated Virus Antibody: Association With Hemophiliacs' Immune Status and Blood Component UsageJAMA, 253
P. Mannucci, Massimo Colombo (1988)
VIRUCIDAL TREATMENT OF CLOTTING FACTOR CONCENTRATESThe Lancet, 332
J. Meer, S. Daenen, G. Imhoff, J. Wolf, M. Halie (1986)
Absence of seroconversion for HTLV-III in haemophiliacs intensively treated with heat treated factor VIII concentrate.British Medical Journal (Clinical research ed.), 292
(1984)
Needlestick transmission of HTLV-111 from a patient infected in Africa (editorial)
C. Ludlam, C. Steel, R. Cheingsong-Popov, D. Mcclelland, J. Tucker, R. Tedder, R. Weiss, I. Philp, R. Prescott (1985)
HUMAN T-LYMPHOTROPIC VIRUS TYPE III (HTLV-III) INFECTION IN SERONEGATIVE HAEMOPHILIACS AFTER TRANSFUSION OF FACTOR VIIIThe Lancet, 326
P. Simmonds, F. Lainson, R. Cuthbert, C. Steel, J. Peutherer, C. Ludlam (1988)
HIV antigen and antibody detection: variable responses to infection in the Edinburgh haemophiliac cohortBritish Medical Journal (Clinical research ed.), 296
H. Jaffe, D. Bregman, Richard Selik (1983)
Acquired immune deficiency syndrome in the United States: the first 1,000 cases.The Journal of infectious diseases, 148 2
D. Fuchs, E. Werner, A. Hausen, M. Dierich, G. Reibnegger, H. Wachter (1988)
Antigen detection in primary HIV infectionBritish Medical Journal (Clinical research ed.), 296
D. Imagawa, H. LeeMoon, Steven Wolinsky, K. Sano, F. Morales, S. Kwok, J. Sninsky, P. Nishanian, Giorgi Jv, J. Fahey, J. Dudley, B. Visscher, R. Detels (1989)
Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods.The New England journal of medicine, 321 24
J. Kreiss, L. Kitchen, H. Prince, C. Kasper, A. Goldstein, P. Naylor, O. Preble (1988)
Human T Cell Leukemia Virus Type Ill Antibody, Lymphadenopathy, and Acquired Immune Deficiency Syndrome in Hemophiliac Subjects
(1987)
Survey of non-U.S. hemophilia treatment centers for HIV seroconversions following therapy with heat-treated factor concentrates.MMWR. Morbidity and mortality weekly report, 36 9
J. Levy, G. Mitra, M. Mozen (1984)
Recovery and inactivation of infectious retroviruses from factor VIII concentration.Lancet, 2 8405
A. Ronde, P. Reiss, J. Dekker, F. Wolf, A. Hoek, T. Wolfs, C. Debouck, J. Goudsmit (1988)
SEROCONVERSION TO HIV-1 NEGATIVE REGULATION FACTORThe Lancet, 332
D. Piszkiewicz, L. Bourret, M. Lieu, K. Hattley, W. Thomas, C. Cabradilla, H. Kingdon, D. Ménaché (1987)
Heat inactivation of human immunodeficiency virus in lyophilized factor VIII and factor IX concentrates.Thrombosis research, 47 2
R. Gerety, D. Aronson (1982)
Plasma derivatives and viral hepatitisTransfusion, 22
Steven Wolinsky, C. Rinaldo, S. Kwok, J. Sninsky, P. Gupta, D. Imagawa, H. Farzadegan, L. Jacobson, K. Grovit, M. Lee (1989)
Human immunodeficiency virus type 1 (HIV-1) infection a median of 18 months before a diagnostic western blot. Evidence from a cohort of homosexual men.Annals of internal medicine, 111 12
J. Craske, P. Kirk, B. Cohen, E. Vandervelde (1978)
Commercial factor VIII associated hepatitis, 1974–75, in the United Kingdom: a retrospective surveyJournal of Hygiene, 80
C. Horsburgh, J. Jason, I. Longini, K. Mayer, G. Schochetman, G. Rutherford, G. Seage, C. Ou, S. Holmberg, C. Schable, A. Lifson, J. Ward, B. Evatt, H. Jaffe (1989)
DURATION OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION BEFORE DETECTION OF ANTIBODYThe Lancet, 334
W.J.W. Morrow, Marcia Wharton, Raphael Stricker, Jay Levy (1986)
Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus.Clinical immunology and immunopathology, 40 3
S. Iwarson, H. Kjellman, A. Teger‐Nilsson (1976)
Incidence of Viral Hepatitis after Administration of Factor IX ConcentratesVox Sanguinis, 31
(1988)
Safety of therapeutic products used for hemophilia patients.MMWR. Morbidity and mortality weekly report, 37 29
J. Allain, D. Paul, Y. Laurian, D. Senn, Members Group (1986)
SEROLOGICAL MARKERS IN EARLY STAGES OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HAEMOPHILIACSThe Lancet, 328
Sydney Gellis, John Neefe, Joseph Stokes, Laurence Strong, Charles Janeway, George Scatchard (1948)
CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XXXVI. INACTIVATION OF THE VIRUS OF HOMOLOGOUS SERUM HEPATITIS IN SOLUTIONS OF NORMAL HUMAN SERUM ALBUMIN BY MEANS OF HEAT.The Journal of clinical investigation, 27 2
A. Prince, B. Horowitz, B. Brotman (1986)
STERILISATION OF HEPATITIS AND HTLV-III VIRUSES BY EXPOSURE TO TRI(n-BUTYL)PHOSPHATE AND SODIUM CHOLATEThe Lancet, 327
DavidA. Cooper, P. Maclean, R. Finlayson, Harry Michelmore, J. Gold, B. Donovan, T. Barnes, Peter Brooke, R. Penny (1985)
ACUTE AIDS RETROVIRUS INFECTION Definition of a Clinical Illness Associated with SeroconversionThe Lancet, 325
F. Hollinger, G. Dolana, W. Thomas, F. Gyorkey (1984)
Reduction in risk of hepatitis transmission by heat-treatment of a human Factor VIII concentrate.The Journal of infectious diseases, 150 2
L. Winkelman, P. Feldman, D. Evans (1989)
Severe heat treatment of lyophilised coagulation factors.Current studies in hematology and blood transfusion, 56
J. Esteban, C. Tai, J. Kay, J. Shih, A. Bodner, H. Alter (1985)
IMPORTANCE OF WESTERN BLOT ANALYSIS IN PREDICTING INFECTIVITY OF ANTI-HTLV-III/LAV POSITIVE BLOODThe Lancet, 326
Clin Lab Haematol, 10
A. Ranki, Minerva Krohn, J. Allain, G. Franchini, S. Valle, J. Antonen, M. Leuther, K. Krohn (1987)
LONG LATENCY PRECEDES OVERT SEROCONVERSION IN SEXUALLY TRANSMITTED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTIONThe Lancet, 330
A. Schreiber, M. Hrinda, J. Newman, G. Tarr, R. D'alisa, W. Curry (1989)
Removal of viral contaminants by monoclonal antibody purification of plasma proteins.Current studies in hematology and blood transfusion, 56
HIV-1 Infection from Concentrates
V. Edwards, J. Mosley (1989)
Reproducibility in quality control of protein (Western) immunoblot assay for antibodies to human immunodeficiency virus.American journal of clinical pathology, 91 1
M. Fletcher, S. Azen, B. Adelsberg, G. Gjerset, J. Hassett, J. Kaplan, J. Niland, T. Odom-Maryon, J. Parker, D. Stites (1989)
Immunophenotyping in a multicenter study: the Transfusion Safety Study experience.Clinical immunology and immunopathology, 52 1
J. Weisser (1988)
Übertragung von Human-Immunodeficiency-Virus (HIV) durch trocken-hitzebehandelte Faktor- VIII-Gerinnungspräparate?Klinische Pädiatrie, 200
Christine Rouzioux, S. Chamaret, Luc Montagnier, V. Carnelli, G. Rolland, P. Mannucci (1985)
ABSENCE OF ANTIBODIES TO AIDS VIRUS IN HAEMOPHILIACS TREATED WITH HEAT-TREATED FACTOR VIII CONCENTRATEThe Lancet, 325
H. Alter, J. Eichberg, H. Masur, W. Saxinger, R. Gallo, A. Macher, H. Lane, A. Fauci (1984)
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS.Science, 226 4674
T. Wolfs, C. Breederveld, W. Krone, L. Hoek, M. Bakker, L. Smit, J. Goudsmit (1988)
HIV-Antibody Seroconversions in Dutch Haemophiliacs Using Heat-Treated and Non Heat-Treated Coagulation Factor ConcentratesThrombosis and Haemostasis, 59
N. Ewing, N. Sanders, S. Dietrich, C. Kasper (1988)
Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors.JAMA, 259 1
W. Berg, J. Cate, C. Breederveld, J. Goudsmit (1986)
SEROCONVERSION TO HTLV-III IN HAEMOPHILIAC GIVEN HEAT-TREATED FACTOR VIII CONCENTRATEThe Lancet, 327
J. Levy, G. Mitra, M. Mozen (1984)
RECOVERY AND INACTIVATION OF INFECTIOUS RETROVIRUSES ADDED TO FACTOR VIII CONCENTRATESThe Lancet, 324
J., S. McDougal, L. Martin, S. Cort, M. Mozen, C. Heldebrant, B. Evatt (1985)
Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.The Journal of clinical investigation, 76 2
J. Kreiss, L. Kitchen, H. Prince, C. Kasper, A. Goldstein, P. Naylor, O. Preble, J. Stewart, M. Essex (1986)
Human T cell leukemia virus type III antibody, lymphadenopathy, and acquired immune deficiency syndrome in hemophiliac subjects. Results of a prospective study.The American journal of medicine, 80 3
J. Weisser (1988)
[Transmission of the human immunodeficiency virus by a dry heat-treated Factor VIII concentrate?].Klinische Padiatrie, 200 5
D. Ho, M. Sarngadharan, L. Resnick, Fulvia diMarzo-Veronese, Rota Tr, M. Hirsch (1985)
Primary human T-lymphotropic virus type III infection.Annals of internal medicine, 103 6 ( Pt 1)
G. Minuk, J. Hoofnagle, V. McAuliffe, R. Purcell (1983)
IgM antibody responses to hepatitis B surface antigen in recipients of hepatitis B virus vaccine.The Journal of infectious diseases, 148 2
(1988)
Case-control study of a cluster of HIV seroconversions among hemophilia patients implicating heat-treated donor-screening factor concentrates
G. White, T. Matthews, K. Weinhold, BartonF. Haynes, H.Leroy Cromartie, C. McMillan, D. Bolognesi (1986)
HTLV-III SEROCONVERSION ASSOCIATED WITH HEAT-TREATED FACTOR VIII CONCENTRATEThe Lancet, 327
P. Felding, I. Nilsson, B. Hansson, G. Biberfeld (1985)
ABSENCE OF ANTIBODIES TO LAV/HTLV-III IN HAEMOPHILIACS TREATED WITH HEAT-TREATED FACTOR VIII CONCENTRATE OF AMERICAN ORIGINThe Lancet, 326
Prevalence of antibody to HIV in hemophiliacs in the United Kingdom : A second survey
Prince (1987)
The development of virus-free labile blood derivatives - A reviewEur J Epidemiol, 3
Abstract. The Transfusion Safety Study monitored susceptible persons for human immunodeficiency virus type 1 (HIV‐1) infections transmitted by plasma products and blood components. Through December, 1988, 6 subjects without antibody to HIV‐1 (anti‐HIV‐1) became seropositive after receiving dry‐heated factor VIII concentrate. The preparations implicated in 3 cases were derived entirely from anti‐HIV‐1‐screened donors. In all instances, HIV‐1 infection could be explained by concentrates heated at 60 °C for 24–30 h. Limiting consideration to concentrates and components administered after study entry showed that 4 of the seroconversions occurred among 122 subjects given 10 million units of factor VIII concentrates. No seroconversions occurred among 84 subjects given 5 million units of factor IX concentrates, or 83 who received components from over 26,000 unpaid donations. Serologic surveillance of anti‐HIV‐1‐negative subjects provides important information, and should be routine in the management of persons receiving clotting factor concentrates.
Vox Sanguinis – Wiley
Published: Oct 1, 1990
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.